Clinical Studies

BD Vialon™ Biomaterial: A proprietary material designed exclusively by BD for vascular access. Clinical studies highlight proven superiority over FEP polymer.

BD Persist™ Skin Prep: An In Vitro Determination of Antimicrobial Efficacy Using a Time Kill Method

BD Persist™ Skin Prep: An In Vivo Determination of Antimicrobial Efficacy

BD Persist™ Skin Prep: Reducing Skin Irritation Under an Occlusive Dressing A Comparison Study

BD Persist™ Skin Prep: Your Best Choice Under an Occlusive Dressing Technical Data Sheet

Clinical Resource Materials for Neonatal Products

Cllinical resource materials enhance knowledge and assist clinicians in optimizing patient care and reducing catheter-related complications.

• Mendelson, M.H., et al. Abstract Summary: Evaluation of a Safety IV Catheter (Insyte Autoguard, Becton Dickinson) using the Centers for Disease Control and Prevention (CDC) National Surveillance Systems for Hospital Healthcare Workers Database. Mount Sinai Med Center, New York, NY.
• Pettit, J. Challenges to providing vascular access in neonatal patients. JVAD, Spring 2000, pgs. 16-21.
• Pettit, J., Hughes, K. Neonatal Intravenous Therapy Practices. JVAD, Spring 1999, pgs. 7-16.
• Stanley M., Meister E., Fuschuber K., Infiltration During Intravenous Therapy in Neonates: Comparison of Teflon® and Vialon™ catheters. Southern Medical Journal, September 1992, Vol. 85, No. 9, pgs. 883-886.
• Maki, D. & Ringer, M. Risk Factors for Infusion-related Phlebitis with Small Peripheral Venous Catheters. Annals of Internal Medicine, Vol. 114, No. 10, 15 May 1991.
• Neonatal IV Therapy Points to Consider

Top of page

Safety Legislation Information

BD Healthcare Worker Safety Site

White Papers

BD Posiflow™ Luer-activated Valve: A needleless connector that when used in conjunction with adequate disinfection procedures, is a barrier to microbial contamination of an IV access device.

Clinical Update

What Shall we do Without Urokinase: The state of IV catheter declotting agents for clearing occluded catheters. History of FDA warnings, citations and communications with the public.

Top of page